Clinical Tests Begin On Medication To Correct Fragile X Defect

Scientists are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability and optimal dosage in healthy volunteers.

Read the whole article on Science Daily

More from Science Daily